Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics

Drug Discov Today. 2024 Apr 18:103986. doi: 10.1016/j.drudis.2024.103986. Online ahead of print.ABSTRACTEED within the PRC2 complex is crucial for chromatin regulation, particularly in tumor development, such that its inhibition is a promising epigenetic therapeutic strategy. Significant advancement in PRC2 inhibitor development has been achieved with an approved EZH2 inhibitor in the market and with others in clinical trials. However, current EZH2 inhibitors are limited to specific blood cancers and encounter therapeutic resistance. EED stabilizes PRC2 and enhances its activity through unique allosteric mechanisms, thereby acting as both a scaffold protein and a recognizer of H3K27me3 making it an attractive drug target. This review provides an overview of epigenetic therapeutic strategies targeting EED, including allosteric inhibitors, PPI inhibitors, and PROTACs, together with brief discussions on the relevant challenges, opportunities, and future directions.PMID:38642703 | DOI:10.1016/j.drudis.2024.103986
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research